Indrayani Biotech Ltd — Important, 19-08-2026: Company Update

IBL Indrayani Biotech's Board has approved the audited financial results for the quarter and year ended March 31. For the year, consolidated revenue stood at **₹137.83 Cr**, with a profit of **₹2.16 Cr**. Standalone revenue was **₹21.90 Cr**, reporting a profit of **₹0.70 Cr**. Auditors issued a qualified opinion on both consolidated and standalone results, citing unresolved balances in loans, trade receivables, and other current assets needing confirmation. Consolidated results also noted issues with two subsidiaries using different accounting standards and a subsidiary lacking trade creditor confirmations, raising concerns about financial clarity for investors.